US$ 29.17
bpc-157 human clinical evidence safety fda warning letter unapproved new drug FDA Issues Warning Letters to Companies Selling Dietary BPC-157 might be the most
Description
The limited blood supply compounds this problem by restricting the delivery of fibroblasts and growth factors needed for repair
in such settings the risk benefit ratio should be reassessed, and preservative-free preparations considered

A preclinical safety evaluation reported no minimal toxic or lethal doses in animals

This matters because poorly organized scar tissue often leads to re-injury